Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.
The objective of this retrospective study was to investigate clinical features and treatment outcomes in patients with angioimmunoblastic T-cell lymphoma (AITL), data of which were collected over a 15-year period. Sixty-five patients diagnosed with AITL were included in the study. About half of the patients (46.2%) presented with poor performance status (ECOG > or = 2); 72.3% of patients belonged to high intermediate or high-risk of IPI and same proportion belonged to Class 2 of PIT (Prognostic index for PTCL-U), and most patients (95.4%) were diagnosed at an advanced stage. At diagnosis, 27 patients (41.5%) presented with malignant pleural effusion, and 22 patients (33.8%) had skin involvement. Most of the initial chemotherapy regimens were anthracycline-based (88.2%). Overall response rate to initial chemotherapy was 86.2% (64.7% of complete response, 21.5% of partial response). The median progression-free survival and overall survival of all patients was 7.1 months (95% CI, 2.8 - 11.4) and 15.1 months (95% CI, 6.7 - 23.5), respectively. Age, performance status, and PIT scores were predictive prognostic factors for survival. In conclusion, although AITLs showed a good response to the initial chemotherapy, their response durations were short; therefore, chemotherapy for AITL should be modified or intensified as in high-dose chemotherapy.
Park
Byeong-Bae
BB
Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ryoo
Baek-Yeol
BY
Lee
Jae H
JH
Kwon
Hyuck C
HC
Yang
Sung H
SH
Kang
Hye J
HJ
Kim
Hyo J
HJ
Oh
Sung Y
SY
Ko
Young H
YH
Huh
Joo R
JR
Lee
Seung S
SS
Nam
Eun M
EM
Park
Keon W
KW
Kim
Jung H
JH
Kang
Jung H
JH
Bang
Soo M
SM
Park
Sarah
S
Kim
Kihyun
K
Park
Keunchil
K
Suh
Cheolwon
C
Kim
Won S
WS
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000494:pharmacology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000276:immunology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic; D011379:Prognosis; D013997:Time Factors; D016896:Treatment Outcome
D018943:Anthracyclines